There are currently 26 active clinical trials seeking participants for Breast Neoplasms research studies. The states with the highest number of trials for Breast Neoplasms participants are California, Texas, Florida and New York.
Evaluation of Vaginal Microbiome as a Biomarker for the Improvement of Vaginal Health in Women With Breast Cancer, ARISE Study
Recruiting
This study evaluates vaginal microbiome as a biomarker to improve vaginal and sexual health in women with breast cancer receiving endocrine therapy. Breast cancer is the most common cancer in United States women, aside from skin cancers. Endocrine therapy is standard treatment for 70% of invasive breast cancers, significantly affecting sexual health and often causing women to change their course of treatment or cease sexual activity. Changes in the vaginal microbiome, which is the collection of... Read More
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
08/26/2024
Locations: Ohio State University Comprehensive Cancer Center, Columbus, Ohio
Conditions: Breast Neoplasms
A Study of Disitamab Vedotin Alone or With Other Anticancer Drugs in Solid Tumors
Recruiting
This clinical trial is studying solid tumor cancers. A solid tumor is one that starts in part of your body like your lungs or liver instead of your blood. Once they've grown bigger in one spot or spread to other parts of the body, they're harder to treat. This is called advanced or metastatic cancer. Participants in this study must have breast cancer or gastric cancer. Participants must have tumors that have HER2 on them. This allows the cancer to grow more quickly or spread faster. There are f... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/19/2025
Locations: Arizona Cancer Center / University of Arizona, Tucson, Arizona +38 locations
Conditions: Breast Neoplasms, Gastroesophageal Junction Adenocarcinoma, HER2 Low Breast Neoplasms, HER2 Positive Breast Neoplasms, Stomach Neoplasms, Triple Negative Breast Neoplasms, Metastatic Breast Cancer, Metastatic Gastric Cancer, Advanced Breast Cancer, Advanced Gastric Cancer
A Study of Sacituzumab Tirumotecan (MK-2870) as a Single Agent and in Combination With Pembrolizumab (MK-3475) Versus Treatment of Physician's Choice in Participants With HR+/HER2- Unresectable Locally Advanced or Metastatic Breast Cancer (MK-2870-010)
Recruiting
The purpose of this study is to compare sacituzumab tirumotecan as a single agent, and in combination with pembrolizumab, versus Treatment of Physician's Choice (TPC) in participants with hormone receptor positive/human epidermal growth factor receptor-2 negative (HR+/HER2-) unresectable locally advanced, or metastatic, breast cancer. The primary hypotheses are that sacituzumab tirumotecan as a single agent and sacituzumab tirumotecan plus pembrolizumab are superior to TPC with respect to progr... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/19/2025
Locations: Ironwood Cancer & Research Centers ( Site 0066), Chandler, Arizona +190 locations
Conditions: Breast Neoplasms
The Intestinal Microbiome in Triple Negative Breast Cancer Treated with Immunotherapy
Recruiting
This study will determine how the intestinal microbiome differs between patients with obesity and early triple-negative breast cancer who achieve a pathologic complete response from preoperative anti-PD-1 immunotherapy (pembrolizumab) versus patients who do not.
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
02/13/2025
Locations: Pennington Biomedical Research Center, Baton Rouge, Louisiana
Conditions: Breast Neoplasms
Study of Abemaciclib and Elacestrant in Patients With Brain Metastasis Due to ER+/HER-2- Breast Cancer
Recruiting
This is a multi-site, global, open-label study that includes a phase 1b evaluation of elacestrant in combination with abemaciclib in women and men with brain metastases from estrogen receptor (ER)-positive, human epidermal growth factor receptor-2 (HER-2) negative breast cancer. Phase 1b was designed to select the recommended phase 2 dose and is followed by an ongoing phase 2 evaluation of elacestrant in combination with abemaciclib in patients with active brain metastases from ER-positive, HER-... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/10/2025
Locations: Providence Medical Foundation, Fullerton, California +76 locations
Conditions: Breast Neoplasms, Brain Neoplasms, Neoplasms by Site, Neoplasms, Breast Diseases, Central Nervous System Neoplasms, Brain Diseases, Central Nervous System Diseases
A Study of DM001 in Patients with Advanced Solid Tumors
Recruiting
The goal of this clinical trial is to find out about the safety, efficacy, and tolerability of DM001 for patients with the advanced solid tumors. DM001 is an experimental drug which is not approved by health authorities for the treatment of advanced solid tumors. Participants will have up to 17 visits during the study.There will be up to a 4-week Screening Period followed by a treatment period that will be divided into 3-week cycles/ Participants will have 5 study visits during Cycle 1, 3 visit... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/05/2025
Locations: University of Texas MD Anderson Cancer Center, Houston, Texas +3 locations
Conditions: Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Solid Carcinoma
Study to Test the Safety and Tolerability of PF-07220060 in Participants With Advance Solid Tumors
Recruiting
This is a Phase 1/2A, open label, multicenter, nonrandomized, multiple dose, safety, tolerability, pharmacokinetic and pharmacodynamic study of PF-07220060 administered as a single agent and then in combination with endocrine therapy. The study consists of two parts and a China and Japan monotherapy cohort. Part 1 includes dose escalation cohorts evaluating PF-07220060 as single agent or in combination with endocrine therapy or enzalutamide, as well as a food effect cohort and a DDI cohort Part... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/02/2025
Locations: Ellison Institute, Los Angeles, California +37 locations
Conditions: Liposarcoma, Prostate Cancer, Breast Neoplasms, Adenocarcinoma of Lung
A Study of Imlunestrant Versus Standard Endocrine Therapy in Participants With Early Breast Cancer
Recruiting
The main purpose of this study is to measure how well imlunestrant works compared to standard hormone therapy in participants with early breast cancer that is estrogen receptor positive (ER+) and human epidermal receptor 2 negative (HER2-). Participants must have already taken endocrine therapy for two to five years and must have a higher-than-average risk for their cancer to return. Study participation could last up to 10 years.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
01/20/2025
Locations: USO - Southern Cancer Center, Daphne, Alabama +702 locations
Conditions: Breast Neoplasms
A Study of Breast Cancer Risk Factors and Outcomes of People in Florida
Recruiting
The purpose of this study is to understand why different people have different risks and outcomes for breast cancer and non-breast cancer.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
01/16/2025
Locations: University of California, Los Angeles (Specimen Analysis only), Los Angeles, California +1 locations
Conditions: Breast Cancer, Breast Neoplasms, Breast Diseases
Safety/Efficacy Study of CID-078 in Patients With Advanced Solid Tumor Malignancies
Recruiting
This is a first-in-human, multicenter, open-label, phase 1 study to evaluate safety, tolerability, and efficacy of CID-078, a Cyclin A/B-RxL inhibitor, in patients with advanced solid tumors.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
12/16/2024
Locations: START Midwest, Grand Rapids, Michigan +6 locations
Conditions: Advanced Solid Tumor, Metastatic Solid Tumor, Refractory Solid Tumor, Cancer, Lung Cancer, Triple Negative Breast Cancer, Breast Neoplasms, Neuroendocrine Tumors, Neuroendocrine Carcinoma
Tirzepatide Weight Loss for MRD+ Early Breast Cancer
Recruiting
This trial aims to asses if tirzepatide-induced weight loss will lead to metabolic and hormonal changes in hormone receptor-positive (HR+), human epidermal growth factor receptor-negative (HER2-), node-positive (N+) high risk early breast cancer patients with obesity or overweight, inhibiting the growth and survival of micrometastatic disease and leading to clearance of tumor-informed circulating tumor DNA (ctDNA) and freedom from the development of metastatic disease.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
11/26/2024
Locations: Baylor University Medical Center, Baylor Charles A Sammons Cancer Center, Dallas, Texas
Conditions: Breast Cancer, Breast Neoplasms, Breast Cancers
(Z)-Endoxifen for the Treatment of Premenopausal Women With ER+/HER2- Breast Cancer
Recruiting
This open-label research study is studying (Z)-endoxifen as a possible treatment for pre-menopausal (still having periods) women with ER+/HER2- breast cancer. (Z)-endoxifen is a selective estrogen receptor modulator or "SERM." SERMs work to treat cancer by blocking the body's natural estrogen from binding to cancer cells. This study includes a pharmacokinetic part (PK, how the drug works in your body) and a treatment part. The primary purpose of the study is to see how (Z)-endoxifen works on tum... Read More
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
10/29/2024
Locations: Mayo Clinic Arizona, Phoenix, Arizona +9 locations
Conditions: Breast Neoplasms, Invasive Breast Cancer, Estrogen-receptor-positive Breast Cancer, HER2-negative Breast Cancer